POSITIVE RESULTS FROM PHASE I CLINICAL TRIAL OF SMT D002 FOR THE TREATMENT OF SEBORRHEA, A PRIMARY CAUSE OF ACNE

We all know that primary cause of acne is excessive sebum production, which is known to be successfully controlled by well known acne drug Roaccutane or Accutane. Roaccutane is known to work in almost all acne patients and it’s considered real acne cure, but in the same time is blamed for serious side effects including depression and mental problems, vision problems, liver intoxication etc. so it cannot be used long-term way. But unbelievable news is coming now from the Oxford,UK. Scientists are claiming that new drug tested under the name of SMT D002 can be used to control sebum production with same results as Roaccutane but without any serious side effects and in completely safe way.

“Acne sufferers all around the Globe are excited about news from the UK. This is a big hope for us.”

Research Summary

Oxford, UK, 15 April 2008, Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, today announces a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhea (excessive sebum production), a primary cause of acne.

According to the study SMT D002 is proven to suppresses sebum levels by 90% in repeat-dose trial.

The study was conducted in 18 healthy volunteers and examined the effect of repeat oral doses of SMT D002 over a four-day period. The key findings of the Phase I clinical trial are:

? Statistically significant levels of sebum suppression (primary endpoint) of 90% when compared to the placebo group (p=0.04)

? SMT D002 proved to be safe with no serious or unexpected adverse side-effects reported
? Sebum levels measured over six hours following treatment using a Sebumeter, an industry accepted method
? Results from trial support a previous positive Phase I single-dose study conducted in nine volunteers

The results of this trial confirm the potential of SMT D002 as a new therapeutic agent for the treatment of seborrhoea in acne patients. Acne is a multi-billion dollar market and it is estimated that there are 54 million patients in the developed world with acne. Approximately eight million acne sufferers are also resistant to current topical retinoid acne treatments and therefore any new and effective treatment is anticipated to gain a sizeable share of this high-value market. In addition, seborrhoea is a non-motor symptom of Parkinson’s disease that is estimated to affect a large proportion of patients.

Summit plans to develop a topical formulation of SMT D002 to further evaluate its efficacy in the treatment of acne and the Company is actively seeking a commercial partner to advance this candidate from the clinic through to the market.

For more information you can download summary of Summit plc drug trial from official site: http://www.summitplc.com/uploads/08_SUMM_05AcnetrialFINAL.pdf

About Company

About Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company’s internal drug development programmes are underpinned by its advanced carbohydrate chemistry and zebrafish drug screening technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neurological disorders, anti-infectives, ophthalmic diseases and oncology.

When it will be available? Regarding the company, if drug pass all the tests, it will be available in 2011-2012 period. In 2009 Phase II testing is expected. It’s said that first it will be available in topical-cream form. It is thought that it would achieve quicker results as a cream treatment. There is a lot of excitement with SMT D002 because of its positive results in acne cases and the fact that it is almost completely free of side effects. In the moment, company is looking for market-partner who will help in commercializing the drug before it become widely available.

For more information, please contact:

Summit plc Tel: +44 (0)1235 443951 Steven Lee, PhD, Chief Executive Officer Darren Millington, ACMA, Chief Financial Officer Richard Pye, PhD, Investor Relations